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Intellectual Property and Access to Essential 
Pharmaceuticals: Recent Law and Policy 
Reforms in the Southern Africa Development 
Community Region 
CHIKOSA BANDA†  
I.  INTRODUCTION: BACKGROUND AND CONTEXT 
The advent of the 1994 Agreement on Trade Related Aspects of 
Intellectual Property Rights (TRIPS)1 has given rise to an 
unprecedented and polarized debate concerning the impact of 
intellectual property rights (IPRs) on access to essential 
pharmaceuticals. This debate has focused on the patent system and the 
role it plays in determining the affordability and accessibility of 
pharmaceuticals, especially in developing countries. The debate has 
largely been between those who contend that patents adversely affect 
access to essential pharmaceuticals and those who claim that patents 
are necessary and essential for the promotion of biomedical research 
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Property Rights, Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade 
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and development (R&D).  
This article contributes to this debate by outlining the flexibilities 
the TRIPS Agreement offers to developing and least developed 
countries (LDCs). It exposes a major weakness of the dominant 
debates surrounding the issue of intellectual property and access to 
medicines in the Southern African Development Community (SADC) 
region and offers a proposal to minimize the international dependence 
on India’s generic medication production. This article argues that the 
current approaches to the reform of patent law in the SADC are 
reductive in as far as they assume that the problem of access to 
pharmaceuticals can be resolved by merely implementing TRIPS 
flexibilities to facilitate the importation of pharmaceuticals from India, 
currently the world’s largest generic manufacturer for developing 
countries.  It contends that addressing the problem of access to 
medicines requires more holistic and sustainable solutions, including 
taking advantage of the decision of the World Trade Organization 
(WTO) General Council on Paragraph 6 of the Doha Declaration on 
the TRIPS Agreement and Public Health (30 August WTO Decision) 
to stimulate local/regional production of pharmaceuticals.  
This paper has six parts.  Part I sets out the background and 
context of this paper.  It argues that reforms aimed at taking full 
advantage of TRIPS flexibilities to import pharmaceutical products 
represent short- and medium-term solutions to existing access to 
medicines problems and are unlikely to provide satisfactory and 
sustainable long-term solutions. Even though Member States 
predominantly rely on imported generic medicines for their healthcare 
needs, “there is a need for local production of medicines as reliance on 
imports may not be sustainable for these countries.”2 
Part II considers the current situation of innovation and access to 
medicines in the SADC region.  It also outlines the major barriers to 
innovation and access in the SADC. The section contends that the 
challenges of pharmaceutical innovation and access in the SADC are 
multiple and multifaceted, and accordingly, they require regional and 
even global solutions to surmount.  Part III discusses the SADC 
regional level policy reforms aimed at harnessing economies of scale 
to stimulate local/regional production of pharmaceuticals. This part 
argues that the fact that most SADC Members States are LDC is 
potentially beneficial to the SADC since individual Member states can 
 
 2.  Nirmalya Syam, Transition Period for LDCs: Implications for Local Production of 
Medicines in the East African Community, RESEARCH PAPERS 59: THE SOUTH CENTRE, 2 
(2014). 
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take advantage of the waivers provided for in the 30 August WTO 
Decision to produce generic pharmaceuticals for export within the 
region. 
Part IV highlights recent domestic level reforms to incorporate 
TRIPS flexibilities. The major observation in this section is that most 
countries in the SADC region have initiated reforms aimed at 
domesticating TRIPS flexibilities. However, this part notes that the 
pace at which these reforms are taking place indicates that these 
countries do not consider these reforms a major priority in their 
national legal and policy environment. This may pose problems for 
local/regional production. 
Part V outlines the challenges that SADC Members face in 
implementing TRIPS flexibilities. The major challenge highlighted in 
this part is the incoherence between national and regional level policies 
and between national level policies. This part argues that it would be 
difficult to make progress towards the realization of the right to access 
pharmaceuticals by addressing these incoherencies. Part VI is the 
Conclusion.  
A.  TRIPS and Access to Pharmaceuticals 
Global efforts to address TRIPS-related public health concerns 
subsequently led to the adoption of the Declaration on TRIPS and 
Public Health (the “Doha Declaration”) by a WTO Ministerial 
Conference held in 2001.3 The Doha Declaration reaffirmed that the 
TRIPS Agreement should be “interpreted in a manner that is 
supportive of WTO Members’ right to protect public health and, in 
particular, to promote access to medicines for all.”4 It also reaffirmed 
the right of states to authorize manufacturers to copy patented 
inventions without the permission of the patent holder during “national 
emergencies or circumstances of extreme urgency.”5 This may include 
the use of devices such as compulsory licensing. Compulsory licensing 
refers to the “state-authorized licensing of generic medicines to be 
produced or bought without the patent owners consent, even though 
this derogates from the brand-name drug’s market exclusivity.”6 
 
 3.  Doha WTO Ministerial Declaration on the TRIPS and Public Health 
[WT/MIN(01)/DEC/220 November 2001], 
https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm (last accessed 
Dec. 8, 2016) [hereinafter Doha Declaration]. 
 4.  Id. para. 4. 
 5.  Id. 
 6.  Reed F. Beall, Randal Kuhn, & Amir Attaran, Compulsory Licensing Often Did Not 
Produce Lower Prices for Antiretrovirals Compared to International Procurement, 34 
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Paragraph 7 of the Declaration exempts LDCs from TRIPS compliance 
with respect to pharmaceutical products until 1 January 2016.7 This 
period has since been extended to 1 January 2033 by the decision of 
the Council for TRIPS of 6 November 2015.8 Paragraph 6 of the Doha 
Declaration recognizes the fact that some WTO Members have limited 
or no pharmaceutical manufacturing capacity. Consequently, they 
could face difficulties “in making effective use of compulsory 
licensing under the TRIPS Agreement.”9 This is because Article 31 of 
the TRIPS Agreement severely restricts the freedom of States to use 
compulsory licenses. The Article provides that a government may only 
authorize use of the subject matter of a patent without the consent of 
the right-holder where such use is “predominantly for the supply of the 
domestic market of the member authorizing such use.”10 Countries 
with insufficient or no manufacturing capacity may not take full 
advantage of compulsory licensing due to their dependence on external 
manufacturers for their domestic needs. The Ministerial Conference, 
accordingly, instructed “the Council for TRIPS to find an expeditious 
solution to this problem.”11 
Pursuant to the above instruction, the General Council of the 
TRIPS subsequently adopted a decision to make it easier for states with 
insufficient manufacturing capacity to import generic medicine in the 
event of a public health crisis. The decision, adopted on 30 August 
2003, waived the application of Article 31 of the TRIPS Agreement in 
favor of countries with insufficient or no manufacturing capacity. It 
made it permissible for Members to grant compulsory licenses for 
exportation of pharmaceutical products to Members with insufficient 
or no manufacturing capacity.12 Paragraph 6 of the decision further 
 
HEALTH AFF. 493 (2015). 
 7.  The paragraph states:  
We also agree that the least-developed country Members will not be obliged, 
with respect to pharmaceutical products, to implement or apply Sections 5 and 7 
of Part II of the TRIPS Agreement or to enforce rights provided for under these 
Sections until 1 January 2016, without prejudice to the right of least-developed 
country Members to seek other extensions of the transition periods as provided 
for in Article 66.1 of the TRIPS Agreement.  
Doha Declaration at para. 7. This was formalized by a subsequent decision by 
the TRIPS Council of 27 June 2002. 
 8.  Council for Trade-Related Aspects of Intellectual Property Rights, Extension of the 
Transition Period under Article 66.1 of the TRIPS Agreement for Least Developed Country 
Members for Certain Obligations with Respect to Pharmaceutical Products (Decision of the 
Council for TRIPS of 6 November 2015- IP/C/73). 
 9.  See Doha Declaration, supra note 3, para. 6. 
 10.  TRIPS Agreement, supra note 1 Article 31(h). 
 11.  Doha Declaration, supra note 3, para. 6.  
 12.  Paragraph 1(b) of the Decision on the Implementation of Paragraph 6 of the TRIPS 
BANDAFINALBOOKPROOF2-16 (DO NOT DELETE) 2/16/2017  2:45 PM 
48 MARYLAND JOURNAL OF INTERNATIONAL LAW [Vol. 31:44 
waives the requirements of Article 31(f) of the TRIPS Agreement in 
order to facilitate the local production of pharmaceuticals by “a party 
to a regional trade agreement within the meaning of Article XXIV of 
the GATT” for exportation to members of a regional trade agreement 
with insufficient or no manufacturing capacity.13 In December 2005, 
the WTO Members adopted a protocol to amend the TRIPS Agreement 
to formalize the decision of 30 August 2003.14 The amendment, known 
as Article 31bis of the TRIPS,  entered into force on 23 January 2017,  
upon ratification by two-thirds of the WTO Members.15 
In addition, LDCs are exempt from implementing the general 
provisions of the TRIPS save for Articles 3, 4, and 5 until 1 July 2021.16 
They are also exempt from implementing, protecting, and enforcing 
patents on pharmaceuticals until 1 January 2033.17 The waiver is in line 
with article 66 of the TRIPS Agreement, which recognizes the “the 
special needs and requirements of least-developed country Members, 
their economic, financial and administrative constraints, and their need 
for flexibility to create a viable technological base.”18 The exemption 
was for an initial period of ten years.19 This period was made subject 
to extension upon a duly motivated request by an LDC.20 
 
and Public Health Agreement.  
 13.  Id.   
 14.  World Trade Organization General Council Decision of 6 December of 2006, 
Amendment of the TRIPS Agreement , Decision Of The General Council , WT/L/641 
(December 6, 2005), https://www.wto.org/english/tratop_e/trips_e/wtl641_e.htm. 
 15.  WTO, WTO IP Rules Amended to Ease Poor Countries Access to Affordable 
Medicines , 2017 News Items , 23 January 2017, 
https://www.wto.org/english/news_e/news17_e/trip_23jan17_e.htm. 
 16.  World Trade Organization–Council for Trade-Related Aspects of Intellectual 
Property Rights, Extension of the Transition Period under Article 66(1) of the TRIPS 
Agreement for Least Developed Country Members, DECISION OF THE COUNCIL FOR TRIPS 
IP/C/64 (June 11, 2013),  https://www.wto.org/english/tratop_e/trips_e/ldc_e.htm.  
 17.  World Trade Organization–Council for Trade-Related Aspects of Intellectual 
Property Rights, Extension of the Transition Period under Article 66(1) of the TRIPS 
Agreement for Least Developed Country Members for Certain Obligations with Respect to 
Pharmaceutical Products, Decision of the Council of TRIPS IP/C/73 (November 6, 2016), 
https://www.wto.org/english/news_e/news15_e/trip_06nov15_e.htm. 
 18.  Article 66 of the TRIPS Agreement provides as follows:  
In view of the special needs and requirements of least-developed country 
Members, their economic, financial and administrative constraints, and their 
need for flexibility to create a viable technological base, such Members shall not 
be required to apply the provisions of this Agreement, other than Articles 3, 4 
and 5, for a period of 10 years from the date of application as defined under 
paragraph 1 of Article 65.  The Council for TRIPS shall, upon duly motivated 
request by a least-developed country Member, accord extensions of this period. 
 19.  Article 66 of the TRIPS Agreement. 
 20.  Id. 
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Commentators have noted that the above flexibilities, transition 
periods, and waivers are “the most important policy options available 
to LDCs to facilitate affordable access.”21 In particular, the transition 
periods are a critical policy instrument for the promotion of local 
production of pharmaceuticals. This is because the non-recognition 
and non-enforcement of patents on foreign products potentially 
ensures that locally produced pharmaceuticals are not excluded from 
the market due to the existence of patents.22 Moreover, the existing 
literature suggests that strong patent protection would stifle 
technological development in LDCs, because it would pose a barrier 
to learning and copying, which are pre-requisites for technological 
development.23 
It is against this background that Article 66 of the TRIPS 
Agreement provides for exemptions that offer LDCs some policy 
space to facilitate the development of local production capacity. It 
gives LDCs an opportunity “to do what developed countries 
themselves had done to build their technological base.”24 This is done 
through the creation of legal environments that permit the copying and 
imitation of technologies. The transition periods, as renowned 
intellectual property researcher Nirmalya Syam notes, have been 
granted to ensure that LDCs are not hampered by intellectual property 
rights “from taking suitable measures to develop a sound and viable 
technological base in different industrial sectors.”25 They are a vital 
tool for the development of a viable technological base, including 
pharmaceutical production capacity.26 As a result, LDCs in the SADC 
region have been presented with an opportunity to take advantage of 
the transition period and develop viable local production capacity for 
pharmaceuticals, and do what India has been doing for some time.27 
 
 21.  Prerna Mingma Bomzan, Sanya Reid, & Mirza Alas Protilo, Submission of the LDC 
Watch to the United Nations High-Level Panel on Access to Medicines, LDC WATCH, 2 
(2016), http://www.unsgaccessmeds.org/inbox/2016/2/28/prerna-mingma-bomzan. 
 22.  Syam, supra note 2, at 2. 
 23.  UNCTAD Secretariat Geneva, The Least Developed Countries Report 2007: 
Knowledge, Technological Learning and Innovation for Development, 103 (2007), 
http://unctad.org/en/Docs/ldc2007_en.pdf. 
 24.  Syam, supra note 2. 
 25.  Id.  
 26.  Mingma Bomzan et al., supra note 21, at 2. 
 27.  See, e.g., William J Bennett, India Pharmaceutical Patent Law and Its Effects on 
Novartis AG v Union of India, 13 WASH. U. GLOBAL L. REV. 535, 535–57 (2014); Sidonie 
Descheemeker, India, Pharmacy of the Developing World: IP, Trade and Access to Medicine, 
3 JURA FALCONIS JG, (2013). Prior to 2005, India was able to supply medicines to other 
developing countries, because it was not granting product patents for pharmaceuticals. This 
position changed in 2005 when India became fully compliant with the TRIPS Agreement and 
started granting protection to pharmaceuticals.  This means that India will not be able to supply 
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One would accordingly expect LDCs to take advantage of these 
transition periods and reform their laws to exclude pharmaceuticals 
from patent protection. Therefore, it is unsurprising that throughout the 
past decade there have been intensive discussions regarding how 
SADC Member States can reform their laws to incorporate 
flexibilities.28 These discussions have triggered and continue to trigger 
patent law reform initiatives in the SADC region.29 
However, these reforms have predominantly focused on how to 
take advantage of the flexibilities in order to facilitate the importation 
of affordable essential medicines from outside the SADC region.30 
Much emphasis has been placed on how states can ensure that their 
legal frameworks facilitate the importation of medicines from 
countries like India. Little discussion has centered on how to take 
advantage of paragraph 6 of the 30 August WTO Decision or Article 
31 bis (3)  to facilitate local or regional production of pharmaceuticals. 
Consequently, the transition periods do not appear to have triggered 
much country-level reforms among the SADC LDCs.31 
Renowned IP and access to medicines advocates K.M. 
Gopakumar and Sangeeta Shashikant rightly observe that the “use of 
flexibilities within and outside the TRIPS Agreement has become the 
 
generic medicines that were patented in the post-2005 era, unless compulsory licenses for 
export are granted. 
 28.  Breaking IP Barriers: Creating Pathways to Medicine Access (October 12–13, 
2015), http://arasa.info/files/5914/5329/2920/Breaking_IP_Barriers_Meeting_Report.pdf 
(describing how countries of the SADC can use the WTO and the European Community 
flexibilities for better access to affordable HIV/AIDS medicines); see also Tenu Avafia, 
Jonathan Berger, & Trudi Hartzenberg, Monitoring Regional Integration in Southern Africa 
Yearbook, TRADE LAW CENTRE FOR SOUTHERN AFRICA, 270–302, 
http://westminsterresearch.wmin.ac.uk/11915/; Tenu Avafia, Jonathan Berger, & Trudi 
Hartzenberg, The Ability of Select Sub-Saharan African Countries to Utilise TRIPs 
Flexibilities and Competition Law to Ensure a Sustainable Supply of Essential Medicines: A 
Study of Producing and Importing Countries, TRALAC WORKING PAPER NO 12 (2006), 
http://www.section27.org.za/wp-content/uploads/2010/10/Avafia-Berger-and-
Hartzenberg.pdf; SADC Pooled Procurement of Essential Medicines and Medical Supplies 
Situational Analysis and Feasibility Study, 
https://www.sadc.int/files/6614/1890/8516/SADC___SADC_POOLED_PROCUREMENT_
OF_ESSENTIAL_MEDICINES_AND_MEDICAL_SUPPLI. . ..pdf. 
 29.  Lonias Ndhlovu, Access to Medicines under the WTO TRIPS Agreement: A 
Comparative Study of Select SADC Countries (unpublished LLD Thesis), UNIVERSITY OF 
SOUTH AFRICA (2014), 
http://uir.unisa.ac.za/bitstream/handle/10500/14185/thesis_ndlovu_l.pdf?sequence=1. 
 30.  Amal Nagah Elbeshbishi, TRIPS and Public Health: What Should African Countries 
Do?, AFRICAN TRADE POLICY CENTRE (2007), 
http://repository.uneca.org/bitstream/handle/10855/13219/bib.%2054458.pdf?sequence=1 
 31.  Mingma Bomzan et al., supra note 21, at 2, 13. The paragraph has been given formal 
legal force by Article 31bis (3) of the TRIPS Agreement. 
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dominant approach to addressing concerns over access to patented 
medical products following the TRIPS patent regime.”32 They note, 
however, that the strategy of using TRIPS flexibilities to facilitate 
access to medicines is problematic, because it is based on a number of 
“unrealistic and flawed assumptions.”33 One assumption is that all 
countries have pharmaceutical manufacturing capabilities.34 This 
assumption is not valid considering that most developing countries are 
net importers of pharmaceuticals and are unable to use compulsory 
licensing without relying on other countries.35 While the 30 August 
WTO Decision allows for compulsory licensing for exportation and 
importation of pharmaceuticals from producing countries, it has 
largely been unused, because it is characterized by complex, 
cumbersome, and tedious procedures and obligations.36  
 
 32.  K.M. Gopakumar & Sangeeta Shashikant, Intellectual Property (IP) and Access to 
Medical Products: A New Paradigm, (Submission to the United Nations Secretary-General’s 
High Level Panel on Access to Medicines) (2016), 
http://www.unsgaccessmeds.org/inbox/2016/2/28/third-world-networkb. 
 33.  Id. at 1. 
 34.  Id. 
 35.  Id. 
 36.  Paragraph 2 of the Decision imposes the following obligations on the importing 
Member:  
(a) to notify the TRIPS Council about its intention to import a needed product or 
needed products. The notification should specify “the name(s) and expected 
quantities of the product(s) needed;” (b) where a product is protected in its 
territory, to confirm that “it has granted or it intends to grant a Compulsory 
License in accordance with Article 31of the TRIPS and the provisions of this 
Decision;” (c) to take measures to ensure that the imported product(s) are utilized 
in line with public health objectives. Accordingly, it is supposed “to take 
reasonable measures within [its] means, proportionate to its administrative 
[capacity] and to the risk of trade diversion to prevent re-exportation of the 
products that have actually been imported into [its territory] under the system.” 
The exporting Member on the other hand is obliged to issue a compulsory license 
for the export of the needed product. The license should contain a number of the 
following conditions: (a) the quantities to be manufactured and exported should 
be restricted to those “necessary to meet the needs of the eligible importing 
Member;” (b) the licensee must export “the entirety” of what it produces under 
the license to the Member state that has notified the TRIPS Council of its need; 
(c) the products must be “clearly identified as being produced under the system.” 
Identification may take the form of specific marking, special packaging, special 
coloring, shaping, and labeling (paragraph 2). The Decision acknowledges that 
the distinct conditions may have an impact on pricing and only requires licensees 
to distinguish their products to the extent that it is “feasible and does not have a 
significant impact on price” (Paragraph 2(b) (ii)). The licensee is also obliged to 
post some information on a website prior to shipment. The post should include 
the following information (a) the amounts to be shipped to specific destinations 
and (b) the features that distinguish the licensed products from the originators’ 
products. The provisions of paragraph 2 have since January 23, 2017, become 
permanently incorporated into the  TRIPS Agreement as paragraph 2 of  the 
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The need to stimulate local production of pharmaceuticals cannot 
be over-emphasized. This is especially so, given that the patent 
landscape in India is changing, and India is under increasing pressure 
to stop making copies of newer medicines. 
Another assumption is that there is global support for the use of 
flexibilities.37 This assumption has limited validity. Currently, 
developing countries, like India, are under a great deal of domestic and 
external pressure to avoid utilizing flexibilities and to adopt TRIPS-
plus standards, which undermine TRIPS flexibilities.38 As a Joint 
Agency Briefing Paper by HAI-Europe OXFAM observes, a variety of 
strategies have been used to apply pressure on LMICs to not use TRIPS 
flexibilities, and/or to introduce additional IP protections, called 
“TRIPS-plus” provisions. In particular, EU-US trade policy has been 
used to keep pushing a range of TRIPS-plus IP measures that support 
the commercial interests of the pharmaceutical industry, while 
damaging opportunities for innovation and access to medicines in 
LMIC.39 
Obviously, there is less pressure on LDCs, because they are 
entitled to take advantage of transition periods, and their 
pharmaceutical industry does not pose a major threat to developed 
countries. Building up local production capacity within LDCs, by 
taking advantage of the transition periods, offers a more viable and 
sustainable solution to the problem of access to medicine that LDC 
residents currently face. 
 
Annex, to the TRIPS Agreement. 
 https://www.wto.org/english/tratop_e/trips_e/wtl641_e.htm 
 37.  Gopakumar & Shashikant, supra note 32. 
 38. Medecins Sans Frontieres (MSF), Untangling the Web of Antiretroviral Price 
Reductions, 18th ed. (2016), http://www.msf.org/sites/msf.org/files/msf_access_utw.pdf. 
According to the MSF report, India is under intense pressure, driven by multi-national 
pharmaceutical companies, to reform its IP policies and laws. It is also under intense pressure 
to sign Free Trade Agreements (FTAs) that will compel it to adopt TRIPS-plus standards and 
effectively undermine its ability to utilize TRIPS flexibilities. One such agreement is the EU–
India draft FTA. Article 2(1) of the EU–India draft FTA provides that “this chapter shall 
complement and further specify the rights and obligations between the Parties beyond those 
under the TRIPS Agreement and other international treaties in the field of intellectual property 
to which they are parties.” See generally Carlos M Correa, Negotiation of a Free Trade 
Agreement European Union–India: Will India Accept TRIPS-Plus Protection?, OXFAM 
GERMANY AND THE CHURCH DEVELOPMENT SERVICE (2009), 
http://www.redge.org.pe/sites/default/files/correa_eu_india_fta.pdf. 
 39.  Trading Away Access to Medicines—Revisited: How the European Trade Agenda 
Continues to Undermine Access to Medicines, HAI-EUROPE AND OXFAM, 7 (2016), 
https://www.oxfam.org/sites/www.oxfam.org/files/file_attachments/bp-trading-away-access-
medicines-290914-en.pdf. 
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The critical point is that the overarching assumption behind the 
dominant approaches to solving access to medicines problems is that 
addressing patent-related barriers to access using flexibilities to 
support importation of pharmaceuticals will be a panacea to all 
problems of access and affordability.40 This is problematic considering 
that obstacles to access to medicines are multiple and multifaceted. 
Inadequate access to medicine in developing countries cannot just be 
reduced to patents. It is attributable to many other factors, which have 
largely been underemphasized in the dominant discourse. These 
include limited local production capacity, high retail prices, duties, 
taxes, markups, and other supply chain costs and limited lucrative 
markets.41 Limited availability and poor affordability of some 
medicines has also been attributed to market dominance by a limited 
number of pharmaceutical companies. For instance, Beran et al. 
contend, that the limited availability and poor affordability of insulin 
is attributable to the domination of the market by three companies 
which account for “90% of the global insulin market in terms of value 
and volume.”42 Apart from stifling competition, the domination of 
these three companies has also adversely impacted on availability of 
insulin in many countries.43  
Article 31bis of the TRIPS, which has supercededthe 30 August 
Decision, deserves the attention of SADC policy makers, because it 
has the potential to address both the problems of limited local 
production and limited lucrative markets. 
B. The Shrinking Role of India as the Pharmacy of the 
Developing World 
Patent law reform initiatives in the SADC region have reflected 
the current overdependence on India as a source of affordable essential 
generic medicines. This is unsurprising given the importance of India 
as “the pharmacy of the developing world.”44 It is critical to ensure, 
 
 40.  See, e.g., Amir Attaran , How Do Patents Affect Access to Essential Medicines in 
Developing Countries, 23 HEALTH AFF. 155–66 (2004). 
 41.  Margaret Ewen & David Beran, Access to Insulin: Current Status and Global Policy 
Implications, Contribution for the United Nations Secretary-General’s High Level Panel on 
Access to Medicines (2016); David Beran, Margaret Ewen, & Richard Laing, Constraints and 
Challenges in Access to Insulin: A Global Perspective, 4 LANCENT DIABETES ENDOCRINAL 
275–85 (2016), http://www.unsgaccessmeds.org/inbox/2016/2/25/margaret-ewen-and-david-
beran. 
 42.  Margaret Ewen & Richard Laing, Constraints and Challenges in Access to Insulin: 
A Global Perspective, LANCENT DIABETES ENDOCRINAL (2016), 
http://www.unsgaccessmeds.org/inbox/2016/2/25/margaret-ewen-and-david-beran. 
 43.  Id.  
 44.  Existing literature reveals that 76 percent of the generic ARVs used in low and 
BANDAFINALBOOKPROOF2-16 (DO NOT DELETE) 2/16/2017  2:45 PM 
54 MARYLAND JOURNAL OF INTERNATIONAL LAW [Vol. 31:44 
however, that other regions of the world, including the SADC 
countries, establish their own manufacturing bases. This is for a 
number of reasons.  
First, the policy space available to India to produce and export 
generic medicines has been largely undermined. Prior to 2005, India 
was not obliged to provide product patent protection for 
pharmaceuticals.45 However, it is now obliged to comply fully with the 
TRIPS Agreement.46 This makes it difficult for Indian companies to 
make and export generic versions of post-2005 patented 
pharmaceuticals to developing countries and LDCs.47 Thus, the future 
access scenario for newer pharmaceuticals looks bleak. Emerging 
evidence suggests that the cost of treatment is on the increase, because 
new pharmaceuticals are widely patented in developing countries, 
including India.48 The future looks even more problematic for the 
SADC region, because most SADC Member States routinely provide 
patent protection for pharmaceuticals through the African Regional 
Intellectual Property Organization (ARIPO) system.49 This has the 
potential to inhibit access to new generations of pharmaceuticals, 
including antiretroviral (ARVs) drugs. The above trend is worrisome 
given that the number of patients who are resistant to older generations 
of ARVs and need newer ARVs is on the increase. 
Second, India is increasingly being pressured by pharmaceutical 
corporations and developed countries to reform its laws to provide 
 
middle-income countries originate from India. SeeMSF, supra note 37.  Ninety-six percent of 
the HIV medicines donor-funded programs rely on are generics, mostly from India. See HIV 
Medicines-Technology and Market Landscape, UNITAID (March 2014), http: //www. 
unitaId.eu/images/marketdynamics/publications/HIV-Meds-Landscape-March.pdf.  
 45.  William Greene, The Emergence of India’s Pharmaceutical Industry and 
Implications for the U.S. Generic Drug Market, OFFICE OF ECON. WORKING PAPER, U.S. 
INTERNATIONAL TRADE COMMISSION NO. 2007-05-A, 1 (2007). 
 46.  Id. 
 47.  Wilbert Bannenberg, Trade, TRIPS and Access to Medicines: Challenges and 
Opportunities for the SADC Region, BRIEFING PAPER FOR SADC MEMBER STATES 
CONSULTATION, BIRCHWOOD , JOHANNESBURG, SOUTH AFRICA, (September 18, 2012), 
http://www.sarpam.net/wp-content/uploads//images+docs/3-the-programme/d-trips-trade-
access-to-medicines/supporting-documents/Briefing-paper-ENGLISH.pdf; NEPAD, 
Strengthening Pharmaceutical Innovation in Africa Designing Strategies for National 
Pharmaceutical Innovation: Choices for Decision Makers and Countries (Final Study Report) 
29 (2010). 
 48.  Ellen ‘t Hoen et al, Driving a Decade of Change: HIV/AIDS, Patients and Access to 
Medicines for All, 14 J. INT’L AIDS SOC. 1-12 (2011), http: 
//www.jiasociety.org/content/14/1/15. 
 49.  Sangeeta Shashikant, The African Regional Intellectual Property Organization 
(ARIPO) Protocol on Patents: Implications for Access to Medicines, 56 SOUTH CENTRE–
RESEARCH PAPERS, 19 (2014), https://www.southcentre.int/wp-
content/uploads/2014/11/RP56_The-ARIPO-Protocol-on-Patents_ENl.pdf. 
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more protection to patent holders than it is required to do under the 
TRIPS Agreement.50 India is also being pressured to relax its standards 
in order to extend patent protection to pharmaceutical products that 
would otherwise not pass the existing criteria for patentability.51 This 
effectively constrains its available policy space to use flexibilities in 
favor of the developing world thus undermining India’s role as a 
supplier of generic pharmaceuticals.52 
Third, as a sovereign state, India has its own pharmaceutical R&D 
priorities, which might not necessarily coincide with the pressing 
public health needs of the SADC region. Therefore, it would be myopic 
to place too much reliance on it. As Ellen ‘t Hoen et al. observe: 
“Without production sources, the countries that rely on importation 
will find it hard to source low-cost medicines.”53 
The importance of developing a regional strategy for addressing 
the gap that the ongoing Indian law and policy reforms might create 
for SADC countries cannot be over-emphasized. Such a strategy needs 
to put strong emphasis on local or regional production of 
pharmaceuticals. The development of local and regional production 
capabilities for SADC countries would ultimately help in the 
development of regional pharmaceutical R&D capabilities for the 
SADC. 
Ironically, most pro-access advocates and SADC policy makers 
tend to define the problem of access too narrowly by concentrating on 
the question of affordability and how to facilitate importation of 
pharmaceuticals from countries like India. This is overly reductive and 
ultimately unhelpful as a way of finding sustainable solutions to the 
problem of access. As Reid and Mirza observe:  
Developing local or regional pharmaceutical 
production capacity is a fundamental aspect of access 
 
 50.  Brook Baker, Will the Modi Government Succumb to U.S. and Industry Pressure to 
Modify its Pro-Access Pharmaceutical Patent Policy? 25 EXPERT OPINION ON THERAPEUTIC 
PATENTS J. 625–28 (2015),  
http://www.tandfonline.com/doi/full/10.1517/13543776.2015.1018890. 
 51.  Medecins Sans Frontieres (MSF), A Timeline of U.S. Attacks on India’s Patent Law 
and Generic Competition, MSF ACCESS CAMPAIGN (2015), 
https://www.msfaccess.org/sites/default/files/MSF_assets/IP/Docs/IP_factsheet_TimelineUS
PressureIndia_ENG_2014.pdf. 
 52. MSF, Decisions Around HIV Treatment in 2015: Seven Ways to Fail, Derail or 
Prevail(2015), 
https://www.msfaccess.org/sites/default/files/HIV_Brief_HIV_Fail_Derail_or_Prevail_ENG
_2015.pdf. 
 53.  Ellen ‘t Hoen et al., supra note 48, at. 7  
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to pharmaceutical products and thus imperative to the 
fulfillment of the right to health. There is growing 
concern of the impact of the overwhelming reliance on 
pharmaceutical imports on affordability, availability 
and long term sustainability.54 
C. The Innovation–Access Balance 
In order to provide sustainable access to medicine, two broad 
challenges must be addressed. The first challenge is how to make 
existing medicines affordable to the poor. The second and more 
intractable challenge relates to how to devise new ways of stimulating 
R&D and local production of new medicines for diseases endemic in 
developing countries.  
Access to medicines will only be achieved if medicines are 
developed and manufactured in the first place, and development 
requires the creation of a legal framework that is supportive of R&D 
and local/regional production. Such a legal and policy framework must 
address both the need to get currently available pharmaceuticals to the 
developing world and the need to encourage research into future useful 
products that benefit the poor (as well as local/regional production of 
the same). This would be in line with the third goal of the UN Strategic 
Development Goals (SDGs), which contain the following bold 
commitment: 
Support the research and development of vaccines and 
medicines for the communicable and non-
communicable diseases that primarily affect 
developing countries, and provide access to affordable 
essential medicines and vaccines, in accordance with 
the Doha Declaration on the TRIPS Agreement and 
Public Health, which affirms the right of developing 
countries to use to the full provisions in the Agreement 
on Trade-Related Aspects of Intellectual Property 
Rights regarding flexibilities to protect public health, 
and, in particular, provide access to medicines for all. 
These are the challenges that SADC Member States have recently 
been attempting to surmount. Thus, the ensuing discussion focuses on 
the legal and policy reforms that have recently been taking place in the 
SADC region in order to stimulate local production of 
 
 54.  Mingma Bomzan et al., supra note 21, at 6. 
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pharmaceuticals. 
II.  THE SADC REGION AND ACCESS TO PHARMACEUTICAL 
PRODUCTS: SADC AND ITS DISEASE BURDEN 
The SADC was established in 1992 by the Treaty of the Southern 
African Development Community.55 The objective of the treaty was 
“to promote sustainable and equitable economic growth and socio-
economic development that will ensure poverty alleviation, with the 
ultimate objective of its eradication, enhance the standard and quality 
of life of the people of Southern Africa and support the socially 
disadvantaged.”56 Regional integration is regarded as a tool for 
achieving these objectives.  
The SADC has fifteen Member States, namely: Angola, 
Botswana, Democratic Republic of the Congo (DRC), Lesotho, 
Madagascar, Malawi, Mauritius, Mozambique, Namibia, Seychelles, 
South Africa, Swaziland, Tanzania, Zambia, and Zimbabwe.57 Eight of 
these Members States are classified as LDCs. These are Angola, 
Malawi, Mozambique, Zambia, DRC, Lesotho, Tanzania, and 
Madagascar.58 The defining characteristics of LDCs include poverty, 
socio-economic inequalities and injustices, low human development, 
economic vulnerability, limited resilience to natural disasters and 
limited technological development.59 The SADC has a population of 
approximately 277 million people.60 
The SADC region is one of the most heavily disease-burdened 
regions of the world. Its Members continue to bear a disproportionate 
burden of HIV/AIDS, tuberculosis (TB), and malaria.61 Non-
communicable diseases (NCDs) are also on the increase, especially in 
 
 55.  The SADC was restructured in 2002 pursuant to major amendments to the 1992 
Treaty. The amendments include, a number of provisions relevant to access to medicines. 
These include Article5(a) cited in note 36 and Article 5(i) which provides that one of the 
objectives of the SADC shall be to “combat HIV/AIDS and other deadly or communicable 
diseases.” 
 56.  Id.  
 57.  See Southern African Development Community, Member States, 
http://www.sadc.int/member-states/. 
 58.  See United Nations Committee for Development Policy, List of Least Developed 
Countries,  http://www.un.org/en/development/desa/policy/cdp/ldc/ldc_list.pdf. 
 59.  Mingma Bomzan et al., supra note 21, at 2.  
 60. SADC Pharmaceutical Programme, SADC Pharmaceutical Business Plan, 5 (2015–
2019) [hereinafter SADC PBP (2015–2019)].   
 61.  See SADC, Communicable Diseases, 
http://www.sadc.int/themes/health/communicable-diseases/. 
BANDAFINALBOOKPROOF2-16 (DO NOT DELETE) 2/16/2017  2:45 PM 
58 MARYLAND JOURNAL OF INTERNATIONAL LAW [Vol. 31:44 
the African middle class.62 
The SADC’s integration agenda primarily focuses on trade, 
economic growth, and development.63 However, the recognition that 
Member States cannot address these challenges individually has 
prompted SADC Members to include health on the SADC integration 
agenda. Consequently, the integration agenda prioritizes the social and 
human development aspects of integration. This includes “fostering 
cooperation in addressing health challenges influenced by the high 
burden of both communicable diseases, such as HIV/AIDS, TB, and 
malaria, and NCDs, such as diabetes, hypertension, cancer, and heart 
problems.”64 The integration agenda also recognizes the interface and 
interaction among poverty alleviation, regional integration, economic 
development, and human rights.65 
Equitable access to medicines remains illusory for the majority of 
SADC citizens.66 While some SADC Member States have relatively 
good access to medicines, others do not.67 There are also wide 
disparities in terms of access within specific countries.68 There are a 
number of barriers to the availability of good quality and affordable 
medicines in the SADC region. These barriers include inadequate 
national medicine budgets; over-dependence on imported medicines; 
inadequate R&D; inadequate local production; under-utilization of 
installed production capacities; poor procurement and supply 
 
 62.  WHO, Baseline Assessment of the Pharmaceutical Situation in Southern African 
Development Community Countries: Fact Book (2009), 
http://www.who.int/medicines/areas/coordination/coordination_assessment/en/index3.html. 
 63.  Article 5 of the SADC Treaty; Amos Saurombe, Regional Integration Agenda for 
SADC “Caught in the Winds of Change” Problems and Prospects, 4 J. INT’L COMM. L. & 
TECH. 100–06 (2009). 
 64.  SADC Pharmaceutical Programme, SADC Pharmaceutical Business Plan, 3 (2007–
2013), 
https://www.unido.org/fileadmin/user_media_upgrade/What_we_do/Topics/Business__inves
tment_and_technology_services/CUP/Pharma/Literature/SADC_PHARMACEUTICAL_BU
SINESS_PLAN_-APPROVED_PLAN.pdf [hereinafter SADC PBP (2007–2013)]. 
 65.  Article 5 of the SADC Treaty. 
 66.  SADC, Strategy for Pooled Procurement of Essential Medicines and Health 
Commodities, 1 (2013–2017), 
https://www.sadc.int/files/7614/1898/8449/SADC___Strategy_for_Pooled_Procurement_of_
Essential_Medicines_and_Health_Commodities.pdf [hereinafter SADC PPEM (2013–2017)]. 
 67. SADC, Pooled Procurement of Essential Medicines and Medical Supplies Situational 
Analysis and Feasibility Study,10 (2012), 
https://www.sadc.int/files/6614/1890/8516/SADC___SADC_POOLED_PROCUREMENT_
OF_ESSENTIAL_MEDICINES_AND_MEDICAL_SUPPLI. . ..pdf[hereinafter SADC 
Feasibility Study]; WHO, Baseline Assessment of the Pharmaceutical Situation in Southern 
African Development Community Countries: Fact B 2009ook,  1 (2009), 
http://www.who.int/medicines/areas/coordination/sadc_final.pdf?ua=1 
 68.  Id. 
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management systems; limited supplier base and small quantity 
requirements69; human resource constraints; taxes and tariffs on raw 
materials and finished products; poor health care infrastructure and 
systems; small markets; and unaffordable prices.70 Outdated IP laws 
are also implicated, especially in developing member states.71 All 
SADC states are Members of the WTO and are obliged to comply with 
minimum standards of IP protection, including patents.72 They are also 
entitled to take advantage of various flexibilities and waivers available 
to them under the TRIPS legal framework. 
The problem of inadequate access to medicines is also aggravated 
by the fact that the majority of SADC citizens have no medical 
insurance. This means that they procure medicines out of pocket.73 
Given low earning capacities, medicine is generally out of reach for 
them.74 Therefore, they rely on under-resourced public-sector health 
service providers for their needs.75 Thus, the individual markets of 
Member States are not attractive to pharmaceutical manufacturers. 
This has implications for affordability and sustained access. 
A.  The SADC Pharmaceutical Market 
The estimated SADC pharmaceutical market is U.S. $4.1 billion, 
largely dominated by generic and patented pharmaceuticals from 
outside Africa.76 In terms of HIV/AIDS specific pharmaceuticals, 
patented pharmaceuticals account for thirty-seven percent while 
generic pharmaceuticals account for sixty-three percent.77 
Local manufacturers account for twenty-four percent of the 
SADC pharmaceutical market.78 The SADC pharmaceutical market is 
largely dominated by South Africa, which has some limited capacity 
to produce active pharmaceutical ingredients (APIs).79 The 
 
 69.  According to the SADC-PBP (2015-2019), supra note 59, these factors effectively 
undermine the procurement-bargaining power of Member States. 
 70.  SADC PBP (2015–2019), supra note 60, at 18. 
 71.  SADC PBP (2007-2013), supra note 64, at 9.  
 72. TRIPS Agreement, supra note 1.  
 73.  Insight Actuaries and Consultants Effective Health Financing Models in SADC: 
Three Case Studies, FINMARK TRUST, 4 (2016), http://www.finmark.org.za/wp-
content/uploads/2016/06/regional-sadc-case-studies.pdf 
 74.  Id.  
 75.  Id. 
 76.  SADC SPPEM (2013-2017), supra note 66, at 11.   
 77.  SADC Feasibility Study, supra note 67, at 30. 
 78.  SADC, Feasibility Study on Regional Manufacturing of Medicines and Health 
Commodities, Volume 1, (Final Report) SADC-SHD&SP/CD/C39/2014, 30 (January 2016). 
 79.  International Finance Corporation (IFC), The Business of Health in Africa: 
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pharmaceutical industry outside South Africa primarily focuses on 
producing “non-complex, high volume, essential products, such as 
basic analgesics, simple antibiotics, anti-malarial drugs, and 
vitamins.”80 
There are a number of factors that undermine local production of 
pharmaceuticals in the SADC region. These factors include strong 
competition from Indian manufacturers; lack of local supply of raw 
materials and overdependence on imported raw materials (from India 
and China); inadequate incentives (low taxes, preferential treatment, 
and loans); and lack of policy coherence on tariffs.81 Additional factors 
include inadequate usage of existing pharmaceutical production 
facilities, due to lack of enabling policy environments; inadequate 
human resource capacity; high operating costs, rendering it more cost 
effective to import; financial resource constraints; obsolete equipment; 
inadequate pharmaceutical manufacturing policies/strategies; and 
absence of and inadequate procurement policies in favor of local 
manufacturers.82 Another factor that undermines local production is 
limited effective demand for local products in individual SADC 
LDCs.83 SADC LDCs generally depend on development partners for 
their pharmaceutical supplies. These development partners either 
require World Health Organization (WHO) prequalification as 
condition for procurement or source their products from elsewhere.84 
This disadvantages some SADC manufacturers who have challenges 
meeting international quality and other WHO prequalification 
standards.85 As a result, Asian countries have a comparative advantage 
 
Partnering the Private Sector to Improve People’s Lives, International Finance Corporation, 
World Bank Group, 76 (2007), 
https://www.unido.org/fileadmin/user_media/Services/PSD/BEP/IFC_HealthinAfrica_Final.
pdf 
 80.  Id.; see also SADC PBP (2007–2013), supra note 64, at 9-10. 
 81.  SADC PBP (2007–2013), supra note 63, at 17; EQUINET, Enhancing Local 
Medicine Production in East and Southern Africa, POLICY SERIES NO.39, 2 (2014), 
http://www.equinetafrica.org/sites/default/files/uploads/documents/EQ_GHD_Meds_polbrie
f39_2014.pdf; Southern and Eastern African Trade, Information and Negotiations Institute 
(SEATINI) and Centre for Human Rights and Development (CEHURD)Literature review on 
bottlenecks to essential medicines production and procurement in East and Southern Africa, 
(2013), 
http://www.equinetafrica.org/sites/default/files/uploads/documents/Diss_96_GHD_Litreview
_meds_May2013.pdf. 
 82.  SADC Feasibility Study, supra note 67, at 16. 
 83.  EQUINET supra note 81, at 2, 
http://www.equinetafrica.org/sites/default/files/uploads/documents/EQ_GHD_Meds_polbrie
f39_2014.pdf. 
 84.  Todd Dickens, The World Medicines Situation in 2011: Procurement of Medicines, 
(WHO-Geneva), http://apps.who.int/medicinedocs/documents/s18769en/s18769en.pdf. 
 85.  Id. at 23. 
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over SADC producers due to a number of factors, in particular, human 
resources, basic costs of production, and experience and economies of 
scale.86 Consequently, it is considered cheaper to source medical 
products from India than to procure within the region. Therefore, a 
need exists to create an enabling legal and policy environment for local 
or regional production of pharmaceuticals products within the region. 
Given the limited manufacturing base in the region, SADC LDCs 
have relied on imports, especially from India, as a source of affordable 
generic pharmaceuticals for their populations. Eighty-five percent of 
these HIV/AIDS generics are produced outside the region and fifteen 
percent are produced in the region.87 
The burden of procuring and providing medicines has essentially 
been borne by development partners.88 As observed above, the future 
access scenario looks bleak, given that India can no longer easily make 
newer versions of generic drugs for export. Therefore, the challenge 
for SADC countries has been to find a more reliable source of second-
line and third-line (or salvage) ARVs.89 This concern has resulted in 
the countries’ increasingly inward search on this issue, and they are 
now actively exploring options for producing generic essential 
medicines within the SADC region itself.90 
Given the magnitude of these problems and the recognition that 
individual countries have serious capacity constraints, SADC Member 
States have resolved to adopt collective approaches to addressing 
access to medicine problems.91 Collective approaches are further seen 
as a way of enhancing market efficiencies and harnessing economies 
of scale.92 
 
 86.  Fei-fei Yue & Ying-ming Yue, Study of Comparative Advantages of Chinese and 
Indian Pharmaceutical Industries under Globalization, 4 MGNT SCI. 82 (2010). 
 87.  Id. 
 88.  SADC SPPEM (2013–2017), supra note 66, at 9. 
 89.  Salvage treatment becomes essential when treatment options become limited due to 
resistance. According to MSF, the current lowest price of the salvage drug Darunavir + 
Raltegravir and Eltravirine (DRV+RAL+ETV) is US $1,859 per person/per year (Untangling 
the Web, 10, 2016). 
 90.  SADC PBP 2015–2019, supra note 60. 
 91.  Id. 
 92.  SADC, Feasibility Study, supra note 67. 
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III.  RECENT LAW AND POLICY REFORMS  
A.  Regional Level Reforms 
The desire to find collective solutions to the common problem of 
inadequate access to medicines has motivated SADC states to develop 
laws, policies, and programs that seek to address this problem in a 
collaborative manner. These include two major developments. First, 
the adoption of the legally enforceable, SADC Protocol on Health in 
1999.93 Article 29 of the Protocol obliges state parties to “cooperate 
and assist one another in the harmonization of procedures of 
pharmaceuticals, quality assurance and registration, production, 
procurement, and distribution of affordable essential drugs.”94 And 
second, the adoption of the SADC Pharmaceutical Business Plan 
(PBP) by SADC Health Ministers in 2006. The PBP was valid from 
2007 to2013.95 A new plan has since replaced it and covers the period 
from 2014 to 2019.96 The PBP is designed to operationalize the SADC 
pharmaceutical program.97 Its stated overall objective is to ensure “the 
availability of essential medicines including African Traditional 
Medicines to reduce the disease burden in the region.”98 At a more 
specific level, the SADC PBP seeks to “improve sustainable 
availability and access to affordable, quality, safe, efficacious essential 
medicines including African Traditional Medicines.”99 
B.  SADC PBP (2015-2019): Strategic Priority 2 
The SADC has recognized promoting local and regional 
production capacity of the pharmaceutical industry as one of the key 
strategic priorities of the PBP. Strategic Priority 2 of the plan focuses 
on “creating an enabling environment that will maximize the research 
and production capacity of local and regional pharmaceutical 
industries in terms of generic essential medicines.”100 The strategies 
adopted to achieve this end include promotion of joint ventures and 
public-private partnerships, and removal of tariff and policy barriers 
on raw materials.101 The envisaged output of the plan is “50% increase 
 
 93.  Protocol on Health in the Southern African Development Community (1999). 
 94.  Article 29(a)(b).  
 95.  SADC PBP (2000–2013), supra note 66. 
 96.  SADC PBP (2015–2019), supra note 60. 
 97.  Id. at 9. 
 98.  Id.at 4. 
 99.  Id. 
 100.  SADC PBP (2015-2019), supra note 60, at 19. 
 101.  The rationale behind these initiatives is that they would enhance the viability of the 
SADC pharmaceutical sector by reducing production costs, harnessing private and public 
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in local production and availability of essential medicines.”102 
C.  Opportunities to Build a Pharmaceutical Industry in the 
Region 
Prior to 2005, the prospects of building a viable generics industry 
in SADC were slim because of fierce competition from India and 
China. These countries have a comparative advantage over SADC 
countries when it comes to the production of raw materials and finished 
products. However, as the SADC Feasibility Study observes, the full 
implementation of the TRIPS Agreement by India presents an 
opportunity for the SADC pharmaceutical sector.103 This is because 
India cannot easily make generic versions of pharmaceuticals that were 
patented post-2005.104 Manufacturers in SADC LDC Members would 
be entitled to make generics until 2033.105 
The PBP 2015-2019 implicitly recognizes the fact that individual 
Member States do not have large enough markets to support a viable 
pharmaceutical industry.106 It therefore sets out strategies that seek to 
take advantage of TRIPS flexibilities to improve pharmaceutical 
manufacturing and distribution capabilities at the regional level. 
Specifically, the PBP recognizes that the TRIPS Agreement does not 
oblige LDCs to implement patent and data protection provisions until 
2033 or even beyond.107 According to the PBP, this presents an 
opportunity for SADC Member States, including LDCs, to take 
advantage of the transition period and develop their local production 
capacity.108 This opportunity was initially recognized in the SADC 
PBP 2007-2013, which provided as follows: “A second window of 
opportunity which could be exploited is contained in paragraph 6 of 
the WTO decision of August 30, 2003, which allows regional blocs 
with at least half of its membership being LDCs to trade in 
pharmaceuticals within the bloc without restrictions.”109 
 
resources, and increasing productivity. 
 102.  Id. at 26. 
 103.  SADC, Pooled Procurement of Essential Medicines and Medical Supplies 
Situational Analysis and Feasibility Study, (2012), 
https://www.sadc.int/files/6614/1890/8516/SADC___SADC_POOLED_PROCUREMENT_
OF_ESSENTIAL_MEDICINES_AND_MEDICAL_SUPPLI. . ..pdf 
 104.  SADC Feasibility Study, supra note 67, at 30. 
 105.  Decision of the Council for TRIPS of 6 November 2015. 
 106.  SADC PBP (2015–2019) supra note 60, at 17. 
 107.  Id. at 17, 20. 
 108.  Id. at 20. 
 109.  SADC PBP (2007–2013), supra note 64, at 12.  
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Paragraph 6 of the 30 August WTO Decision endeavors to solve 
the problems of insufficient manufacturing capacity and the absence 
of lucrative domestic markets by attempting to harness economies of 
scale using regional trade groupings.110 The paragraph exempts 
developing countries or LDCs that are members of certain regional 
trade agreements from some TRIPS obligations.111 These include the 
requirement under Article 31(f) of the TRIPS Agreement that 
compulsory licensing should be, predominantly, for domestic use.112 
The only countries that can take advantage of this exemption or 
waiver, however, are those that are members of regional trade 
agreements, whose membership comprises at least fifty percent 
LDCs.113 The scope of the waiver is to enable members to produce or 
import pharmaceutical products under a compulsory license so those 
members can export to the markets of other developing or LDC 
members within the trade block that share the health problem in 
 
 110.  The paragraph reads as follows:  
 With a view to harnessing economies of scale for the purposes of enhancing 
purchasing power for, and facilitating the local production of, pharmaceutical 
products: “where a developing or least-developed country WTO Member is a 
party to a regional trade agreement within the meaning of Article XXIV of the 
GATT 1994 and the Decision of 28 November 1979 on Differential and More 
Favourable Treatment Reciprocity and Fuller Participation of Developing 
Countries (L/4903), at least half of the current membership of which is made up 
of countries presently on the United Nations list of least developed countries, the 
obligation of that Member under Article 31(f) of the TRIPS Agreement shall be 
waived to the extent necessary to enable a pharmaceutical product produced or 
imported under a compulsory license in that Member to be exported to the 
markets of those other developing or least developed country parties to the 
regional trade agreement that share the health problem in question. It is 
understood that this will not prejudice the territorial nature of the patent rights in 
question”; (SADC is a regional body notified Article XXIV of the GATT). 
 111.  Paragraph 6 (i) of the 30 August Decision. The Paragraph has now become 
permanently incorporated into the TRIPS by Article 31bis (3) which provided as follows:  
 With a view to harnessing economies of scale for the purposes of enhancing 
purchasing power for, and facilitating the local production of, pharmaceutical 
products: where a developing or least developed country WTO Member is a party 
to a regional trade agreement within the meaning of Article XXIV of the GATT 
1994 and the Decision of 28 November 1979 on Differential and More 
Favourable Treatment Reciprocity and Fuller Participation of Developing 
Countries (L/4903), at least half of the current membership of which is made up 
of countries presently on the United Nations list of least developed countries, the 
obligation of that Member under Article 31(f) shall not apply to the extent 
necessary to enable a pharmaceutical product produced or imported under a 
compulsory licence in that Member to be exported to the markets of those other 
developing or least developed country parties to the regional trade agreement 
that share the health problem in question. It is understood that this will not 
prejudice the territorial nature of the patent rights in question.” 
 112.  Id. 
 113.  Id. 
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question.114 
The waiver attempts to harness the economies of scale to enhance 
the existing purchasing power through use of regional trade blocs, and 
promote and facilitate local production of pharmaceutical products.115 
The PBP 2015-2019 recognizes the potential utility of the 30 
August WTO Decision as a tool for promoting local/regional 
production of pharmaceuticals in key Strategic Area 7.116 Paragraph 
7(v) of the PBP stipulates that, in order to facilitate trade in 
pharmaceuticals within the region, SADC members will “utilize the 
paragraph 6 system or article 31bis of the TRIPS Agreement to 
facilitate local production for export; or importation for re-exportation 
within SADC as a regional bloc.”117 The difficulty is that SADC LDCs 
may not have the capacity to reap the full benefits of this waiver 
because of the absence of lucrative domestic markets, human resource 
constraints, inadequate technological capacity, poor infrastructure, and 
inadequate public funding of R&D.118 Some country studies have 
revealed, however, that various individual SADC countries have some 
production capacity and could benefit from the economies of scale that 
Article 31bis attempt to harness.119 Article 31 bis  is flexible enough to 
allow for the possibility of the manufacture of pharmaceuticals to take 
place in developing country member states. Therefore, SADC 
countries can explore the possibilities of harnessing the R&D, as well 
as production and procurement capabilities of some of its developing 
member states, including South Africa, to achieve this objective. 
Moreover, while individual SADC countries and the region at 
large may not represent lucrative markets for big pharmaceutical 
companies, the SADC region may be a large enough market for 
 
 114.  Id.  
 115.  Id. 
 116.  SADC PBP (2015–2019), supra note 60, at 20. 
 117.  Id. 
 118.  LDC Watch, supra note 21, at 4. 
 119.  John H Amuasi, Technology Transfer and Local Manufacturing of Pharmaceuticals: 
The South African Case, African Dialogue on Technology Transfer for Local Manufacturing 
Capacity on Drugs and Vaccines Cape Town, South Africa, ICTSD AND UNCTAD, WITH THE 
SUPPORT OF THE WHO AND THE EU COMMISSION, 10–11 (December 2009), , 
http://www.ictsd.org/downloads/2009/12/amuasi-paper-edited.pdf; United Nations Industrial 
Development Organization Pharmaceutical Sector Profile Zimbabwe: Global UNIDO 
Project: Strengthening the local production of essential generic drugs in least developed and 
developing countries, (2011),  
http://apps.who.int/medicinedocs/documents/s18701en/s18701en.pdf; German Technical 
Cooperation Agency (GTZ),The Viability of Local Pharmaceutical Production in Tanzania, , 
4, 43 (2007), https://www.unido.org/fileadmin/user_media/Services/PSD/BEP/Tanzania.pdf. 
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regional manufacturers. Hence, the Article 31 bis  attempts to create 
viable markets by allowing companies in individual countries to 
produce for export within the region. 
Some LDCs in the region already have some pharmaceutical 
manufacturing capacity, albeit limited.  As a result they may be 
potential leaders in manufacturing pharmaceuticals for the SADC 
region. A recent study on Tanzania, for instance, concluded that there 
is a case for promoting local production in Tanzania.120 This is 
especially because the public sector, which is mostly supported by 
donors, represents a relatively significant market and “offers realistic 
options for a viable business.”121 The same can be said of other SADC 
countries.122 The study also concludes that a regional approach to 
pharmaceutical production would make more business sense.123 The 
only drawback is that most domestic companies do not meet WHO 
prequalification standards to be eligible for international donor 
financing.124 
LDCs within the region could also explore the possibility of 
collaborating with Indian, Chinese, Brazilian, U.S., and EU 
manufacturers to open generic plants within their territories, which 
would service the whole SADC region. Such collaborations are already 
emerging within the region and in the Common Market for Eastern and 
Southern Africa (COMESA) area. Mozambique, for instance, has 
recently started producing generic and older versions of ARVs with 
assistance from Brazil.125 
Moreover, utilization of this system would facilitate “the 
development of a viable technological base, including pharmaceutical 
production capacity.”126  This is because the system endeavors to solve 
the problem of limited markets for pharmaceuticals within individual 
countries and attempts to harness economies of scale within regional 
blocs. The flexibility to produce for export would render the SADC 
region attractive to generic pharmaceuticals investors and would hence 
help in the development of a technological base for the region. 
Therefore, the system provides a window of opportunity for countries 
 
 120.  Id. 
 121.  GTZ, The Viability of Local Pharmaceutical Production in Tanzania, 4, 43 (2007), 
https://www.unido.org/fileadmin/user_media/Services/PSD/BEP/Tanzania.pdf. 
 122.  South Africa, Zimbabwe, Zambia and Mozambique. 
 123.  Id. at 44. 
 124.  SADC Feasibility Study, supra note 67. 
 125.  Bannenberg, supra note 47, at 3. 
 126.  Mingma Bomzan et al., supra note 21.   
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within the SADC region to do what India has been doing for some 
time. 
Developed countries also have an obligation to perform in the 
development of a viable pharmaceutical base for the SADC region. 
Article 66 of the TRIPS Agreement obliges them to “provide 
incentives to enterprises and institutions in their territories for the 
purpose of promoting and encouraging technology transfer to least-
developed country Members in order to enable them to create a sound 
and viable technological base.”127 However, there is evidence 
suggesting that developed countries have not honored their 
commitment to transfer technology to LDCs.128 Nevertheless, this 
should not be a reason to rule out local production. Rather, it should be 
a reason to advocate for developed countries to honor their 
commitments. Given that SADC LDCs have no capacity to make 
newer pharmaceuticals, including ARVs, they would require a lot of 
technical and financial support from development partners to develop 
production capabilities.   
Moreover, there is emerging evidence that developing countries 
have started transferring essential technologies to developing countries 
and LDCs. Thailand, for example,  transferred technology for the 
formulation of a fixed-dose combination of stavudine, lamivudine, and 
nevirapine to two companies based in Tanzania and the DRC.129 Action 
Medeor, a German non-governmental organization (NGO), has been 
involved in an initiative to develop a fixed dose combination 
formulation of tenofovir, lamivudine, and efavirenz in collaboration 
with Muhimbili University in Tanzania. The expectation is that the 
technology would be transferred to local manufacturers at no cost.130 
Similarly, the Brazilian government was recently involved in a transfer 
of technology initiative through the Oswaldo Cruz Foundation 
(FIOCRUZ) to the government of Mozambique, which constructed a 
new ARV manufacturing plant.131  
Technology transfer by itself, however, would not facilitate 
technological development in LDCs. Effective use of such technology 
 
 127.  Doha Declaration, supra note 3, para. 7. The Doha Declaration also reaffirms “the 
commitment of developed-country Members to provide incentives to their enterprises and 
institutions to promote and encourage technology transfer to least-developed country 
Members pursuant to Article 66.2.” 
 128.  WHO Pharmaceutical Production and Related Technology Transfer  (2011),  
http://www.who.int/phi/publications/Local_production_and_access_to_medicines.pdf. 
 129.  Id. at 29 
 130.  Id.  
 131.  Id. 
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in an LDC context would require building the capacity of 
pharmaceutical companies in LDCs to assimilate such knowledge and 
“adopt technical know-how.”132 Domestic patent legislation can also 
facilitate this process by ensuring that patents are not granted unless 
the inventor describes the invention in such a way that it can be worked 
by locals. SADC countries may wish to adopt a provision similar to 
Section 21(10) of the Ugandan Industrial Property Act, 2014, which 
provides that the registrar may, before granting the patent, require the 
description in a foreign patent application to be adapted to the ordinary 
skill in the art of the citizens of Uganda so as to ensure technology 
dissemination.133 
SADC countries would also need to adopt a regional strategy to 
create a viable market. The recently adopted SADC Strategy for 
Pooled Procurement of Essential Medicines and Health Commodities 
is, thus, a step in the right direction.134 This is because it endeavors to 
eliminate duplication of efforts and to harness economies of scale.135 
To conclude, the system represents a significant policy option 
available to SADC member states to stimulate access to affordable 
medicine at the regional level. Given that some SADC members are 
also members of COMESA136, Article 31 bis  presents an amazing 
potential for smaller SADC states to harness economies of scale. 
Uganda, a COMESA member, has already amended its law to support 
the manufacture and export to other countries that share similar health 
problems.137 These would include SADC members who double as 
COMESA members.138 Section 44(e) of the Ugandan Act provides that 
unauthorized use of a patented invention does not amount to an 
infringement where the manufacture and export of a patented 
healthcare invention to another country  
 
 132.  Syam, supra note 2, at 4.  
 133.  Section 21(10). 
 134.  The SADC Strategy for Pooled Procurement of Essential Medicines and Health 
Commodities was adopted in 2013 and will expire in 2017. The stated aim of the strategy is 
to “facilitate regional cooperation in the procurement of essential medicines and health 
commodities thus ensuring access to affordable, safe, effective and quality–assured products.” 
The idea behind the strategy is to promote market efficiencies and bargaining power through 
regional approaches to procurement. It is hoped that pooled procurement would increase 
access to essential medicines and the availability of orphan drugs that are characterized by 
procurement challenges owing to the limited amounts required by individual states. 
 135.  Paragraph 6(i) of the 30 August Decision. 
 136.  These include Malawi, Mauritius, Zambia, Seychelles, Mauritius, Zimbabwe, and 
Tanzania. 
 137.  Section 44(e) of the Uganda Industrial Property Act. 
 138.  See supra note 139. 
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addresses a health need identified by the other country, 
where(i) the product is either not patented in the third 
country; or 
(ii) the government of another country has authorized 
use of the patent without the consent of the patent 
owner and the production for export of the invention is 
intended only for the market of the third country.139 
These provisions position Uganda perfectly to take 
advantage of the 30 August waiver to export 
pharmaceuticals to COMESA and some SADC nations.  
IV.  DOMESTIC LEVEL REFORMS 
All SADC states are members of the WTO.140 They are generally 
obliged to comply with the TRIPS Agreement.141 However, as stated 
above, LDCs are exempt from applying some general provisions of the 
TRIPS until 2021 and pharmaceutical related provisions until 2033.142 
The possibility of utilizing the above transition periods to exclude 
pharmaceuticals from patentability offers LDCs an opportunity to 
develop a base for manufacturing generic pharmaceutical products.  
The transition period has generally not been utilized, however, by 
most LDCs within the SADC region. This is in contrast with their East 
African counterparts, Uganda,143 Rwanda,144 and Burundi,145 who have 
recently amended their legislation to take advantage of the transition 
period and exclude pharmaceuticals from patent protection.146 Most 
 
 139.  The Industrial Property Act (2014). 
 140.  For a list of WTO Members see 
https://www.wto.org/english/thewto_e/whatis_e/tif_e/org6_e.htm. 
 141.  TRIPS Agreement supra note 1, Article 1.  
 142.  The Decision of the Council of the TRIPS of 6 November 2015. 
 143.  Section 8 (3)(f) of the Uganda Industrial Property Act (2014). 
 144.  Article 18 of the Rwanda Intellectual Property Act (2009). 
 145.  Article 17 of the Burundi Industrial Property Act. 
 146.  See Article 18 of the Rwandan Industrial Property Act, 2009, Article 17 of the 
Burundi Industrial Property Act. Section 8(3)(f) of the Ugandan Industrial Property Act, 2014 
reads:  
The following shall not be regarded as inventions and shall be excluded from 
patent protection—pharmaceutical products and test data until 1st January 2016 
or such other period as may be granted to Uganda or least developed countries 
by the Council responsible for administering the Agreement on trade related 
aspects of intellectual property under the World Trade Organization.  
Article 102 (15) of the Ugandan Act provides that  
the rights accruing from patents for pharmaceutical processes shall not be 
enforceable until January 1, 2016, or such other period as may be granted to 
Uganda or least developed countries by the council responsible for administering 
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SADC LDCs still maintain patent laws that they inherited from their 
colonial masters.147 As a recent SADC commissioned study observed, 
virtually all SADC countries have not taken advantage of the 
pharmaceutical transition periods and “permit pharmaceutical 
patenting.”148 The only exception is Zanzibar, part of Tanzania, which 
has a separate law to exclude pharmaceuticals from patent 
protection.149 Apart from prematurely according patent protection to 
pharmaceutical products, these laws contain provisions that give more 
protection to patent owners than required by the TRIPS Agreement.150 
This is problematic given that transition periods were granted “in view 
of the special needs and requirements of least-developed country 
Members, their economic, financial and administrative constraints, and 
their need for flexibility to create a viable technological base.”151 
A number of reasons may be given as to why this is the case. First, 
these countries believe that compliance with the TRIPS Agreement can 
benefit them by creating incentives for innovation. Second, these 
countries are advised by agencies, such as World Intellectual Property 
Organization (WIPO) that strong patent regimes stimulate domestic 
innovation. However, existing studies reveal that protection and 
enforcement of patents stimulate local innovation “only if 
accompanied by high levels of economic and infrastructural 
development, educational attainment and economic freedom.”152 A 
study by Margaret Kyle and Yi Qian also concludes that “the existence 
of IPRs is neither necessary nor sufficient for the launch of 
 
the agreement on trade related aspects of intellectual property under the WTO if 
alternative processes for making pharmaceutical products that are not subject to 
exclusive rights are not available and those patents, if enforced, indirectly give 
rise to market exclusivity of the pharmaceutical products in question. 
 147.  These include Malawi, Zambia, Swaziland, and Lesotho. 
 148.  Sisule Musungu, Pharmaceutical Patents, TRIPS Flexibilities and Access to 
Medicines in Southern African Development Community (SADC), Report for a SADC member 
States Consultation (September 18, 2012). 
 149.  Section 3(1) of the Zanzibar Industrial Property Act (2014) 
 150.  For example, The Malawi Patents Act, Section 30 provides for the extension of patent 
terms beyond the basic term provided for in Section 29. This extension obviously goes beyond 
the requirements of the TRIPS Agreement. Section 30 exceeds the requirements of TRIPS 
given that the Agreement does not oblige Members to extend patents beyond their basic term. 
See Robert Lettington & Chikosa Banda, A Survey of Policy and Practice on the Use of Access 
to Medicines Related TRIPs Flexibilities in Malawi, DFID (2004), 
http://www.who.int/hiv/amds/countries/mwi_SurveyUseTRIPs.pdf. Additionally, the TRIPS 
Agreement does not oblige LDCs to provide protection for patents . However, the SADC 
countries as we have seen above maintain patent protection for pharmaceuticals. 
 151.  TRIPS Agreement supra note 1, Article 66(1). 
 152.  Qian Yi, Do National Patent Laws Stimulate Domestic Innovation in a Global 
Patenting Environment?, 89 REV. ECON. & STATs. 436 (2007). 
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pharmaceuticals at country level.”153 On the contrary, it might 
adversely impact the freedom of manufacturers to make generic 
versions of essential pharmaceuticals and to broaden their product 
range.154 It is difficult to imagine how SADC LDCs can develop a 
technological base if they prematurely comply with all the provisions 
of the TRIPS Agreement. The premature implementation of the TRIPS 
Agreement would stifle the development of useful products in LDCs 
by preventing “reverse engineering” and by obstructing access to 
research tools and platform technologies.155 This would, in turn, 
hamper the ability of these LDCs to develop technological capacity, 
including pharmaceutical R&D and production capacity.156 
Nevertheless, most SADC countries have revised or have 
embarked on the process of revising their IP laws to incorporate or 
update TRIPS flexibilities. These include Malawi, Seychelles,157 
Namibia,158 Zanzibar,159and Botswana.160 The progressive country level 
legal reforms include incorporation of Article 31bis of the TRIPS 
Agreement.161 Some LDCs are developing laws that exclude 
 
 153.  Margaret Kyle & Yi Qian , Intellectual Property Rights and Access to Innovation: 
Evidence from TRIPS, 23 NAT’L BUREAU OF ECON. RESEARCH, WORKING PAPER NO. 20799 
(2013). 
 154.  Syam, supra note 2, at 6. 
 155.  Innovation in the Least Developed Countries: Going Beyond Intellectual Property 
Rights, LDC Report Highlights-Based on the Least Developed Countries Report, UNCTD, 2 
(2007), http://unctad.org/en/docs/ldcrh2_en.pdf. 
 156.  Id. 
 157.  Seychelles Industrial Property Act (2014). 
 158.  NAMIBIA INDUSTRIAL PROPERTY ACT (2012). 
 159.  ZANZIBAR INDUSTRIAL PROPERTY ACT (2014). 
 160.  BOTSWANA INDUSTRIAL PROPERTY ACT (2010). 
 161.  Section 31(1) of the Botswana Industrial Property Act (2010) authorizes the Minister 
to issue compulsory licenses in the public interest. Section 31(3) of the Act, however, waives 
the “domestic market” condition by providing as follows: The exploitation of the patented 
invention under subsection 1shall be for the supply of the domestic market in Botswana only, 
except where paragraph 1 or 3 of Article 31bis of the TRIPS Agreement applies. Section 32(2) 
provides that “the importation of the patented product by a Government agency or any 
authorized person shall be solely for public non-commercial use within Botswana, except 
where paragraph 1 or 3 of Article 31bis of the TRIPS Agreement is applicable.” Similarly, 
section 57(1)(e) of the Namibia Industrial Property Act (2012) also domesticates article 31bis 
of the TRIPS Agreement. It provides that where a patent relates to a pharmaceutical product 
in respect of which Namibia has insufficient or no manufacturing capacity as contemplated in 
the decision of the General Council of the WTO of August 30, 2003 or in Article 31bis of the 
TRIPS and a License for the importation of the patented product is required” the Minister may 
issue a “compulsory license to exploit an invention including by importation. Section 14 of 
the Zanzibar Industrial Property Act (2014) recognizes compulsory licensing for importation 
pursuant to “the decision of the General Council of the WTO of 30th August 2003.” Section 
97(3) of the Act states:  
compulsory license shall be available for manufacture and export of patented 
pharmaceutical products to any country having insufficient or no manufacturing 
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pharmaceuticals from patentability. Zambia has a draft law which 
purports to exclude pharmaceuticals from patentability until it 
graduates from LDC status.162 Zanzibar has a similar provision in its 
law.163 Consequently, SADC countries are adopting legal provisions 
aimed at taking advantage of the 30 August waiver to facilitate the 
importation of drugs from countries that have generic production 
capacities. The legal provisions are also designed to facilitate the 
production for export and importation for re-export of medicines 
within the region.164 South Africa is in the process of reviewing its 
patent policy.165 Failure to accelerate the implementation of TRIPS 
flexibilities may be symptomatic of the fact that SADC countries do 
not consider implementing TRIPS flexibilities as a human rights 
obligation. Conversely, the African Union Resolution 141 on Access 
to Health and Needed Medicines in Africa calls upon states to take 
measures to promote, protect, and fulfill access to medicines.166 
Specifically, the Resolution recognizes access to pharmaceuticals as 
an indispensable element of the right to a highest attainable standard 
of health.167 Accordingly, it urges states to promote access to 
pharmaceuticals by avoiding measures that negatively impact access. 
These include “implementing intellectual property policies that do not 
take advantage of all the flexibilities in the . . . TRIPS Agreement that 
promote access to affordable medicines.”168 Failure by states to 
appreciate the human rights basis of their obligations may explain their 
 
capacity in the pharmaceutical sector for the concerned product to address public 
health problems or needs, provided compulsory license or authorized use of the 
patent has been granted by such country. 
 162.  Section 16 of the Zambian Patents Bill (2010) provides as follows: 
Pharmaceutical products and processes shall not be patentable until 1 January 
2016 or until the expiry of such later period of extension as may be agreed upon 
by the World Trade Organization for least developed countries.” Section 68(3) 
empowers the Registrar promptly to “reject all pharmaceutical and medicines 
related micro-biological patents until 1 January 2016 or until the expiry of such 
later period of extension as may be agreed upon by the World Trade Organization 
for least developed countries. 
 163. Section 3(1) of the Zanzibar Industrial Property Act (2014) excludes pharmaceutical 
products and processes from patent protection “until January 1, 2016 or the expiry of such 
later period of extension as agreed upon by the WTO Council for the TRIPS.” 
 164.  In order to take advantage of the 30 August waiver. 
 165.  The Policy partly aims at promoting access to essential medicines. See DEP’T OF 
TRADE AND INDUSTRY, DRAFT NATIONAL POLICY ON INTELLECTUAL PROPERTY, 5 (2013), 
http://ip-unit.org/wp-content/uploads/2013/09/DRAFT-IP-POLICY.pdf.  
 166.  Resolution on Access to Health and Needed Medicines in Africa, The African 
Commission on Human and People’s Rights, Meeting of its 44th Ordinary Session held in 
Abuja Nigeria, AU RESOLUTION 141, 10–24 (September 2005), 
http://www.achpr.org/sessions/44th/resolutions/141/.  
 167.  Preamble of the resolution. 
 168.  Paragraph 1.  
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laxity in domesticating TRIPS flexibilities. 
V.  CHALLENGES 
One of the major challenges to implementing TRIPS flexibilities 
in the SADC region is policy incoherence. A good number of SADC 
LDCs still provide patent protection for pharmaceuticals despite the 
fact that they are not obliged to do so under the TRIPS Agreement. 
This is because LDCs view IP as a vital tool for achieving their 
developmental objectives.169 The understanding may be attributable to 
the technical assistance these countries receive from WIPO and other 
development partners.170 
While SADC member states are increasingly incorporating 
TRIPS flexibilities in national legislation, the actual usage of these 
flexibilities still remains limited.171 This is partly attributed to a number 
of factors, including inadequate capacity in the region to implement 
these flexibilities in practice, inadequate awareness of the flexibilities, 
and pressure from developed countries against the use of 
flexibilities.172 The impact of this is that SADC countries cannot take 
full advantage of Article 31 bis  which allows members to produce 
pharmaceuticals for export to other members. Failure to incorporate or 
utilize flexibilities also means that members cannot utilize the system 
provided for under Article 31 bis  to import medicine from outside the 
region for re-exportation to other members within the SADC. In this 
respect, SADC members appear to be motivated more by the desire to 
protect their sovereignty than the need to solve common problems. 
This has accordingly delayed the full implementation of the SADC 
PBP. 
Ten LDCs, five of which are SADC states, are ARIPO 
members.173 ARIPO was created in 1976 by the Agreement on the 
 
 169.  See submission by Sangeeta Shashikant and Gopakumar Kapoori to the UN Secretary 
General’s High Level Panel on Access to Medicines, March 1, 2016, 
http://www.unsgaccessmeds.org/inbox/2016/3/1/third-world-networkc. 
 170.  See submission by Sangeeta Shashikant and Gopakumar Kapoori to the UN Secretary 
General’s High Level Panel on Access to Medicines, March 1, 2016, 
http://www.unsgaccessmeds.org/inbox/2016/3/1/third-world-networkc. 
 171.  See Sisule Musungu, Pharmaceutical Patents, TRIPS Flexibilities and Access to 
Medicines in Southern African Development Community (SADC), REPORT FOR A SADC 
MEMBER STATES CONSULTATION, (September 18, 2012)..  
 172.  See, e.g., UNAIDs, Intellectual Property and Access to Health Technologies (2016), 
http://www.unaids.org/sites/default/files/media_asset/JC2820_en.pdf. 
 173.  Lusaka Agreement on the Creation of the African Regional Organization on 
Intellectual Property Rights (ARIPO) (1976), 
http://www.wipo.int/edocs/lexdocs/treaties/en/ap001/trt_ap001_001en.pdf. 
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Creation of the African Regional Industrial Property Organization 
adopted at Lusaka, in Zambia.174 The objectives of ARIPO include 
promoting the harmonization and development of the industrial 
property laws among member states. ARIPO also aims at 
strengthening “cooperation between states in respect of protection and 
exploitation of patents.”175 The following SADC countries are 
members of ARIPO: Botswana, Lesotho, Malawi, Mozambique, 
Namibia, Swaziland, Tanzania, Zambia, and Zimbabwe. 
The ARIPO Secretariat is responsible for granting patents on 
behalf of member states under the Harare Protocol on Patents and 
Industrial Designs. The Secretariat undertakes formal and substantive 
examinations of patent applications to ensure compliance with the 
prescribed formal requirements and substantive criteria for 
patentability.176 When a patent is granted by ARIPO, designated states 
are supposed to be notified and given a chance to reject the patent.177 
A designated state is given six months to communicate in writing to 
ARIPO that the granted patent shall have no effect in its territory. The 
Harare Protocol makes available to states two grounds for rejecting 
ARIPO granted patents: first, that the invention is not patentable under 
the provisions of the protocol, and second, that “because of the nature 
of the invention, a patent cannot be registered or has no effect under 
the” state’s national law.178 Failure by the designated state to respond 
to a notification within six months renders the patent effective in its 
territory.179 
One major drawback of the Harare Protocol is that it does not 
recognize LDC transition periods, granted under Article 66 of the 
TRIPS Agreement and extensions thereof.180 As a result, it is not 
uncommon for ARIPO to grant pharmaceutical patents in which LDCS 
are designated. This is worrisome considering that most members of 
ARIPO are LDCs and maintain patent laws that do not exclude 
pharmaceuticals from patentability. In fact, existing studies reveal that 
rejection of ARIPO patents is uncommon. Most LDCs routinely accept 
pharmaceutical patents granted by ARIPO partly because of lapses in 
 
 174.  Agreement on the Creation of the African Regional Industrial Property Organization. 
 175.  See the Preamble to the Harare Protocol on Patents and Industrial Designs within the 
Framework of the African Regional Intellectual Property Organization. 
 176.  Section 3 (2)(a) and section 3(3) of the Harare Protocol. 
 177.  Section 3(6) of the Harare Protocol. 
 178.  Section 3(6) of the Harare Protocol. 
 179.  Section 3(7) of the Harare Protocol. 
 180.  Syam, supra note 2, at 8. 
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the notification and objection systems.181 As Robert Lewis-Lettington 
and Chikosa Banda have observed, this “means that ARIPO standards 
are de facto emerging as a uniform regional standard that may, in the 
future, need to be examined in its own right.”182 
Given the implications of the ARIPO system for the use of 
transition periods and other flexibilities, it is high time the ARIPO 
system be thoroughly scrutinized. In this context, commentators have 
recommended that “the Harare Protocol should exempt the territory of 
LDCs from the grant of pharmaceutical patents.”183 This would not be 
a farfetched idea. The Organisation Africaine de la Propriété 
Intellectuelle (OAPI), which is ARIPO’s counterpart in francophone 
Africa, has amended its treaty to provide for the non-applicability of 
pharmaceutical patents to LDCs. Article 46 of the OAPI agreement 
provides that 
Member States that are LDCs are not obliged to 
implement the provisions of Annex 1 regarding patents 
consisting of, or related to, a pharmaceutical product, 
nor to implement the provisions of Annex VIII 
regarding confidential information, until 2033 or on the 
date on which they stop to be classified as an LDC.184 
Incorporating a provision similar to the terms above, into the 
Harare Protocol, would ensure coherence between regional and the 
progressive patent law reforms that are taking place in LDCs. 
Without addressing the above policy contradictions, it will be 
difficult for SADC members to make progress in safeguarding access 
to medicines and stimulating local/regional production of 
pharmaceuticals. 
VI.  CONCLUSION  
The adoption of the SADC PBP and the increasing incorporation 
of TRIPS flexibilities in the domestic laws present a vital window of 
opportunity for member states to take advantage of TRIPS flexibilities 
 
 181.  Sisule Musungu, Access to ART and other Essential Medicines in Sub-Saharan 
Africa:  Intellectual Property and Relevant Legislation (2007), http: 
apps.who.int/medicinedocs/documents/s18248en/s18248en.pdf; Lettington & Banda, supra 
note 150, at 33; Shashikant, supra note 49. 
 182.  Lettington & Banda, supra note 150, at 33. 
 183.  Shashikant, supra note 49, at x. 
 184.  Organisation Africaine de la Propri. . .t. . . Intellectuelle (OAPI), Article 46. (1977), 
http://www.oapi.int/index.php/fr/oapi/cadre-juridique/accord-de-bangui. 
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and waivers in order to promote local/regional production of 
pharmaceuticals.  A number of challenges and barriers need to be 
surmounted, however, in order to make local and regional production 
a reality. First, SADC countries have been over-dependent on India as 
a source of generic pharmaceuticals and have given inadequate 
attention to the implication of post-2005 Indian law and policy reforms 
on future access to medicine. This has obviated the need to develop 
local and regional production capacity and reform domestic legislation 
in order to support local production. Second, the SADC PBP is not 
legally binding. Hence, Members have the option of whether to 
implement it or not. Third, SADC members have, historically, had 
limited expertise in IP law. This has undermined progress in law 
reform. 
Recent developments in the SADC region suggest, however, that 
countries are increasingly becoming aware of the need to find 
sustainable solutions to the problem of how to access pharmaceutical 
products. Consequently, they have initiated law patent law reform 
processes that seek to take full advantage of flexibilities, including the 
transition periods, in order to stimulate local and regional production 
of pharmaceuticals. 
While this is a welcome development, the pace at which SADC 
LDCs are reforming their laws is worrisome. This is evidenced by the 
fact that only one SADC LDC has, to date, enacted a law that takes 
advantage of the transition periods. As noted above, there are a number 
of factors behind this, which include inadequate in-country technical 
and technological capacity, inappropriate TRIPS-related technical 
assistance programs, and pressure from developed countries.  
A number of concrete steps can be taken to accelerate the pace at 
which SADC countries are adopting flexibilities. First, the SADC 
should amend its Protocols on Health and Trade185 in order to 
incorporate TRIPS-related access to medicines provisions. These 
provisions should oblige all Member States to domesticate flexibilities 
and LDCs to take advantage of the TRIPS pharmaceutical waiver. This 
would pave way for the prioritization of these issues in national legal 
and policy frameworks. SADC can also take advantage that the 
majority of its members are LDCs and take advantage of the Article 31 
bis  to facilitate local/regional production of pharmaceuticals. 
Incorporating the foregoing provisions into a legally binding protocol 
would accelerate their adoption by Members. Second, the SADC 
 
 185.  Southern African Development Community (SADC) Protocol on Trade (1996). 
BANDAFINALBOOKPROOF2-16 (DO NOT DELETE) 2/16/2017  2:45 PM 
2016] ACCESS TO ESSENTIAL PHARMACEUTICALS 77 
should recognize that access to essential medicines is a human right. 
Accordingly, individual Members have an obligation to go beyond 
rhetoric and take concrete steps towards the progressive realization of 
this right.  One strategy towards this would be to popularize the 
implementation of African Union Resolution 141, which calls upon 
states to promote, implement, and fulfill access to medicines by 
adopting TRIPS flexibilities and taking advantage of the TRIPS 
waivers. Third, there is an urgent need for financial and technical 
assistance to enable Members to incorporate TRIPS flexibilities. Much 
of the progress that SADC Members have registered to date has come 
from the technical support rendered by the Southern African Regional 
Program on Access to Medicines and Diagnostics (SARPAM). This 
program has since expired, and it is imperative that new regional 
vehicles of technical assistance be established to complete the work 
that SARPAM started. Moreover, Article 67 of the TRIPS Agreement 
opens up a window of opportunity for SADC Members to request for 
and receive technical assistance from developed countries. It obliges 
developed countries to “provide technical and financial cooperation in 
favor of developing and least-developed country Members.”186 The 
cooperation envisaged by this provision includes “assistance in the 
preparation of laws and regulations on the protection and enforcement 
of intellectual property rights.”187 The TRIPS Agreement, thus, 
contains inbuilt mechanisms to facilitate the acceleration of the 
implementation of its provisions, including its flexibilities and 
waivers. The pace at which reforms will take place will largely depend 
on the performance of the above obligations by developed and 
developing states, including LDCs. Given that the implementation of 
the TRIPS flexibilities is undermined by inadequate expertise, it would 
be useful to provide post-reform technical support to LDCs. LDCs 
would require support in order to effectively implement TRIPS 
flexibilities and waivers in practice.188 
However, it would be difficult to promote the incorporation of 
TRIPS flexibilities and the adoption of TRIPs waivers unless SADC 
countries see the direct relevance of the flexibilities to their respective 
countries. At present, most SADC LDCs do not see the direct 
implications of failure to incorporate TRIPS flexibilities for access to 
newer pharmaceuticals. This is because they have no viable 
technological base and are heavily dependent on India for their 
pharmaceutical needs.  As Médecins Sans Frontières (MSF) observes, 
 
 186.  TRIPS Agreement supra note 1, at Section 67.  
 187.  Id. 
 188.  Lettington & Banda,  supra note 149, at 41. 
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“extending the period of TRIPS implementation is just one step in 
addressing the unique challenges of LDCs in Africa but above all there 
is need to address the underlying issues beyond extensions such as 
helping LDCs build their technological base.”189 
Consequently, a viable manufacturing base cannot be created 
without external support. Developed countries have an obligation 
under Article 66(1) of the TRIPS Agreement to encourage LDCs to 
create a good and viable technological base. This would be by 
provision of incentives to enterprises and institutions in their territories 
for the purpose of promoting and encouraging technology transfer to 
LDC members. Developed countries must also help SADC generic 
manufacturers to develop the capacity to produce pharmaceuticals that 
meet WHO prequalification standards. Given the limited nature of the 
market in individual states, this would help create a regional and donor 
market for such pharmaceuticals. 
SADC Members need to understand the important role 
local/regional production of pharmaceuticals can play in addressing 
the gap left by changes in the Indian IP landscape. They also need to 
understand the potential utility of flexibilities and waivers as tools for 
the development of a viable technological base to support generic 
production. In short, the domestication of TRIPS flexibilities would 
only be accelerated if LDC members appreciate tangible benefits of 
doing so. 
 
 189.  MSF, supra note 37, at 16.   
